Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Better characterization of vinflunine pharmacokinetics variability and exposure/toxicity relationship to improve its use: analyses from 18 trials

Abstract : Aims Vinflunine is a novel tubulin-targeted inhibitor indicated as a single agent for the treatment of bladder cancers after failure of prior platinum-based therapy. Its pharmacokinetics (PK) and pharmacodynamics (PD) have been independently characterized through several phase I and phase II studies. However, no global pharmacometric analysis had been conducted yet. Methods Vinflunine concentrations and safety data from 18 phase I and phase II studies were used to conduct population PK and PK/PD analysis, using Nonmem. A 4-compartment model was used to describe vinflunine PK and several covariates were tested in order to explain inter-individual variability. In terms of PK/PD relationship, a semi-physiologic population PK/PD model was applied to describe time course of absolute neutrophil counts (ANC) after vinflunine administration and logistic regression models were used to test the relationship between vinflunine exposure and toxicities. Results Vinflunine clearance is explained by creatinine clearance, BSA and combination with pegylated doxorubicin, leading to a decrease from 28.2 to 25.3% of the inter-individual variability. When vinflunine dose is decreased, simulations of ANC time course (via a semi-physiological model) after vinflunine administration show a risk of neutropenia grade 3-4 at cycle 2 always lower than when dose is delayed. As an example, for moderate renal impaired patients, the risk is 42.1% when vinflunine is dosed at 320 mg/m2 q4w vs. 23.3% for 280 mg/m2 q3w. Conclusions We propose for the first time a global comprehensive clinical pharmacological analysis for IV vinflunine that may help drive dose adjustment.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01716300
Contributeur : Lnc - Université de Bourgogne <>
Soumis le : vendredi 23 février 2018 - 15:10:32
Dernière modification le : mercredi 10 juin 2020 - 14:06:52

Lien texte intégral

Identifiants

Citation

Antonin Schmitt, Laurent Nguyen, Grégoire Zorza, Pierre Ferré, Aurélie Pétain. Better characterization of vinflunine pharmacokinetics variability and exposure/toxicity relationship to improve its use: analyses from 18 trials. British Journal of Clinical Pharmacology, Wiley, 2018, 84 (5), pp.900-910. ⟨10.1111/bcp.13518⟩. ⟨hal-01716300⟩

Partager

Métriques

Consultations de la notice

132